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tations in mismatch repair (MMR) genes (MLH1, MSH2, MSH6,
or PMS2) develop a rare but severe variant of Lynch syndrome
called constitutional MMR deficiency (CMMRD). This syndrome
is characterized by early-onset colorectal cancers, lymphomas
or leukemias, and brain tumors. There is no satisfactory
method for diagnosis of CMMRD because screens for mutations
in MMR genes are noninformative for 30% of patients. MMR-
deficient cancer cells are resistant to genotoxic agents and
have microsatellite instability (MSI), due to accumulation oferrors in repetitive DNA sequences. We investigated whether
these features could be used to identify patients with CMMRD.
METHODS: We examined MSI by PCR analysis and tolerance to
methylating or thiopurine agents (functional characteristics of
MMR-deficient tumor cells) in lymphoblastoid cells (LCs) from
3 patients with CMMRD and 5 individuals with MMR-proficient
LCs (controls). Using these assays, we defined experimental
parameters that allowed discrimination of a series of 14 pa-
tients with CMMRD from 52 controls (training set). We then
used the same parameters to assess 23 patients with clinical




ATbut not genetic features of CMMRD. RESULTS: In the training
set, we identified parameters, based on MSI and LC tolerance to
methylation, that detected patients with CMMRD vs controls
with 100% sensitivity and 100% specificity. Among 23 patients
suspected of having CMMRD, 6 had MSI and LC tolerance to
methylation (CMMRD highly probable), 15 had neither MSI nor
LC tolerance to methylation (unlikely to have CMMRD), and 2
were considered doubtful for CMMRD based on having only 1
of the 2 features. CONCLUSION: The presence of MSI and
tolerance to methylation in LCs identified patients with CMMRD
with 100% sensitivity and specificity. These features could be
used in diagnosis of patients.Keywords: Colon Cancer; Functional Tests; Predisposition;
Tumor.
ndividuals with Lynch syndrome (LS) harbor germline*Authors share co-first authorship; §Authors share co-senior authorship.
Abbreviations used in this paper: 6-TG, 6-thioguanine; CMMRD, consti-
tutional mismatch repair; evMSI, ex vivo microsatellite instability; FAP,
familial adenomatous polyposis; gMSI, germline microsatellite instability;
IHC, immunohistochemistry; LCL, lymphoblastoid cell line; LS, Lynch
syndrome; MMR, mismatch repair; MNNG, N-methyl-N-nitro-N-nitro-
soguanidine; MSI, microsatellite instability; NF1, neurofibromatosis type 1;
PBLs, peripheral blood lymphocytes; VUS, variant of unknown functional
significance.
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http://dx.doi.org/10.1053/j.gastro.2015.06.013Iheterozygous mutations affecting one of the four major
mismatch repair (MMR) genes (ie, MLH1, MSH2, MSH6, or
PMS2) and are at greatly increased risk of developing colo-
rectal and other epithelial tumors.1 Typically, individuals
with germlineMLH1 orMSH2 defects develop MMR-deficient
cancers during their 4th or 5th decade, whereas those with
MSH6 or PMS2 mutations are affected less consistently. Pa-
tients with bi-allelic germline mutations in MMR genes suffer
from constitutional MMR deficiency (CMMRD),2–5 a distinct
inherited cancer syndrome (Online Mendelian Inheritance in
Man [OMIM] database accession no. 276300).6 This syn-
drome is characterized by the development of childhood tu-
mors such as early-onset colorectal cancers, lymphomas/
leukemias, and brain tumors.6–8 Because CMMRD is mainly
due to bi-allelic inheritance of PMS2 or MSH6 germline mu-
tations, the family history of patients shows only a low inci-
dence of LS-related cancers in first- and second-degree
relatives. To date, CMMRD has been reported in 146 patients
from 91 distinct families. Because of variable clinical pre-
sentation, lack of unequivocal diagnostic features, and
phenotypical overlap with other cancer syndromes (eg,
neurofibromatosis type 1 (NF1), Li-Fraumeni, syndrome, fa-
milial adenomatous polyposis [FAP]), CMMRD syndrome is
frequently unrecognized by clinicians and its incidence is
almost certainly underestimated.
In the European Care for CMMRD consortium
(C4CMMRD), we recently proposed clinical diagnostic
criteria that should raise the suspicion of CMMRD when
observed in a child or young adult cancer patient, based on
the phenotypic presentation.9 The suspected diagnosis then
needs to be either confirmed or refuted. The current diag-
nosis of CMMRD requires identification of bi-allelic, delete-
rious germline MMR defects. Unfortunately, mutation
analysis leads to non-informative results when variants of
unknown functional significance (VUS) are detected, as
observed in around 30% of patients. Moreover, the detec-
tion of PMS2 alterations responsible for 60% of CMMRD
families is complicated by the presence of numerous pseu-
dogenes, resulting in a lack of sensitivity when performing
mutation analysis only. Hence, although extensive mutation
screening that includes comprehensive searches for largegenomic rearrangements of MMR genes remains crucial for
identification of CMMRD patients and genetic counseling in
CMMRD families, tests that can unequivocally confirm or
refute a suspected diagnosis are highly desirable.
Because all CMMRD patients share a common and spe-
cific functional property (ie, MMR deficiency), we hypothe-
sized that the detection of characteristic functional features
of MMR-deficient blood cells from such patients could be
used to diagnose this syndrome. Inactivation of MMR is
known to increase cellular tolerance to specific genotoxic
agents such as methylating and thiopurine drugs.10–15
Moreover, MMR-deficient cancer cells specifically exhibit a
microsatellite instability (MSI) phenotype due to accumu-
lation of replication errors in repetitive DNA sequences.16 In
tissues derived from MMR-deficient neoplastic cells, MSI is
easily detected through PCR amplification of microsatellites.
However, earlier studies have shown that MSI cannot be
detected in the germline DNA of CMMRD patients except by
using the laborious technique of “small pool PCR.”6,17
The presence of somatic mutations within DNA repeats in
MMR-deficient cells is related to cell division. We therefore
hypothesized that in vitro culture of immortalized lympho-
blastoid cells from CMMRD patients would eventually lead
to the onset of both an MSI phenotype and tolerance to
methylating/thiopurine agents.
In the present work we first validated the proof of
concept that MSI and tolerance to methylating/thiopurine
agents could be detected in lymphoblastoid cell lines (LCLs)
derived from several CMMRD patients, but not in LCLs from
MMR-proficient controls including LS patients. In a case-
control study, we next determined the experimental condi-
tions that allowed accurate discrimination of a series of
CMMRD patients from MMR-proficient controls. Finally, we
tested our functional approach using the same experimental
conditions in a series of patients who showed clinical char-
acteristics of CMMRD but for whom the standard diagnostic
method was non-informative. This was performed within a
European Consortium “Care for CMMRD” (C4CMMRD) that
allowed us to collect a unique series of confirmed CMMRD
cases and at-risk individuals for this syndrome.Methods
Patients
At the first workshop of the European Consortium, “Care for
CMMRD” (C4CMMRD), held in Paris on June 9, 2013, a call was













ATmade to contribute blood samples or LCLs from definite or
possible CMMRD patients. Eligible subjects included patients
already diagnosed with CMMRD (ie, with bi-allelic deleterious
germline mutations in any of the 4 major MMR genes, as well as
patients with a strong clinical suspicion of CMMRD (ie, with a
clinical score 3 according to Wimmer et al9). LCLs were
available (n ¼ 10) or were established (n ¼ 27) for 37 of the 42
eligible patients. MMR-proficient LCLs used as controls origi-
nated from 47 LS patients and 15 subjects considered free of
MMR germline defects including patients with FAP or NF1
syndrome. All patients gave written informed consent. This
study was approved by the institutional review boards/ethics
committees of the participating centers.
Mutation screening of MMR genes
All analyses were performed in clinically approved labora-
tories. Analysis of the MLH1, MSH2, and MSH6 genes was per-
formed across different laboratories whereas analysis of PMS2
was performed in the Rouen, Lille, or Innsbruck laboratories.
Bi-directional Sanger sequencing from genomic DNA or direct
cDNA sequencing18 was performed to identify point mutations in
exonic and flanking intronic regions. Sequencing reactions were
performed using the ABI PRISM Kit (Applied Biosystems,
Waltham, MA) and sequences were analyzed on an automated
sequencer (ABI 3130XL Genetic Analyzer; Applied Biosystems)
using sequencing analysis software version 5.2 (Applied Bio-
systems).19 Screening for large rearrangements in the MLH1,
MSH2, and MSH6 genes was performed using multiplex ligation-
dependent probe amplification and/or quantitative multiplex
PCR of short fluorescent fragments. Rearrangements of the PMS2
gene were analyzed by quantitative multiplex PCR of short fluo-
rescent fragments for exons 6, 7, 8, and 10, or by multiplex
ligation-dependent probe amplificationusing the SALSAMLPAkit
P008 (MRC-Holland, Amsterdam, the Netherlands) together with
appropriate reference DNAs that have an equal (2:2) distribution
of gene- and pseudogene-derived sequences in exons 13-15.20 In
patient C26, PMS2 exon 12 deletion escaped detection by multi-
plex ligation-dependent probe amplification butwas identifiedby
direct cDNA sequencing. Screening for the NF1 gene was per-
formed by using a variety of methodologies including DNA and
RNA sequencing for small lesions, polymorphic microsatellite
marker analysis, and multiplex ligation-dependent probe ampli-
fication or real-time PCR-based gene dosage analysis to allow
assessment of microdeletions, as previously described.21 Muta-
tion analysis of theAPC genewas performed by direct sequencing
and Multiplex Ligation-dependent Probe Amplification.22
Lymphoblastoid Cell Lines
LCLs obtained following standard Epstein-Barr virus infec-
tion were grown in RPMI 1640 medium with stable glutamine,
supplemented with 20% fetal calf serum, 100 IU/mL penicillin,
and 100mg/mL streptomycin (PAA). Only LCLs with compa-
rable growth rates and with viability greater than 85% were
included.
Ex Vivo Microsatellite Instability Analysis
PCR products following amplification of the NR27, NR21
and BAT26 microsatellites were separated by capillary elec-
trophoresis on an ABI 3100 genetic analyzer and quantified
using Gene Mapper software v3.7 (Applied Biosystems). Inorder to confidently detect allelic shifts of as little as 1 base pair
in size, DNA from LCL and peripheral blood lymphocytes
(PBLs) were analyzed concurrently in octuplicate.
Chemicals
All chemicals were obtained from Sigma unless otherwise
indicated. Cells were exposed to 6-Thioguanine (6-TG) and
N-Methyl-N’-Nitro-N-Nitrosoguanidine (MNNG) (TCI Europe,
Zwijndrecht, Belgium). To exclude differences in MNNG cyto-
toxicity due to variations in O6-methylguanine methyltransfer-
ase enzyme activity, the latter was abrogated by exposure to
O6-benzylguanine (20 mM final concentration) during the entire
experiment. All chemicals were dissolved in DMSO to a con-
centration of 20 mmol/L, protected from light and stored at
20C until used.
Methylation Tolerance Assay
Exponentially growing lymphoblastoid cells were seeded
into 96-well round-bottom plates at a density of 0.15-1104
cells/well. After 24-hour incubation, extemporaneously recon-
stituted MNNG solution was added at 1.25, 2.5, and 5 mmol/L
final concentration. Because of the short half-life of MNNG in
aqueous solution (1 hour), the medium was not replaced after
drug treatment and 1, 2, or 3 rounds of treatment separated by
24 hours were performed. Cell growth was evaluated after a
total incubation time of 10 days and all samples were tested in
triplicate. Each experiment was conducted at least in duplicate.
Cytotoxicity was examined by the WST kit according to the
supplier’s recommendations (Roche, Indianapolis, IN). Absor-
bance was read at 450 nm using a microplate reader (Tecan
Infinite F500; Tecan, Männedorf, Switzerland) and analyzed
using Xfluor4GENiosPro software (Tecan). Percentage of cell
survival was represented as the absorbance of treated sample
relative to control.
Statistical Analyses
A Metropolis-Hastings algorithm was used to estimate the
sensitivity and specificity of the three different diagnostic
methods (MMR gene sequencing, functional testing, gMSI
testing). This algorithm was applied to results obtained from
genetically confirmed CMMRD patients, control patients, and
patients with a strong clinical suspicion of CMMRD but without
a molecularly confirmed diagnosis. Further information is
available in Supplementary Materials and Methods.Results
Proof-of-Concept Study
We first investigated whether MSI and methylation/thi-
opurine tolerance could be detected in LCLs from 3 CMMRD
patients with bi-allelic deleterious mutations in MSH6, PMS2
or MLH1, but not in LCLs from 5 negative controls
comprising 4 LS patients (MSH6, MSH2, PMS2 or MLH1
heterozygous mutations) and one individual with wild-type
MMR status.
MSI screening. As expected, MSI was not detected in
PBLs from CMMRD patients (Figure 1A) following the
analysis of 3 mononucleotide microsatellite markers
(NR27, NR21, BAT26) that are used routinely to assess MSI





October 2015 Functional Diagnosis of CMMRD Syndrome 1021status in tumor cells. In contrast, a clear MSI phenotype
showing characteristic, aberrant alleles was observed in
LCLs from all 3 CMMRD patients (Figure 1A), whereas the 5
control LCLs displayed stable allelic profiles (Figure 1B).
The MSI phenotype was only demonstrated ex vivo in LCLs
and was thus termed evMSI to distinguish it from the
in vivo MSI phenotype detected in MMR-deficient cancer
cells.
Drug tolerance assay. We first evaluated the cytotoxic
effects of MNNG (methylating agent) and 6-thioguanine (6-
TG, thiopurine) in 11 human colorectal cancer cell lines. Cell
lines that were MLH1-, MSH2-, or MSH6-deficient were on
average up to 10-foldmore tolerant to 1mMMNNG thanMMR-
proficient cell lines and 2-fold more tolerant to 15mM 6-TG
(Supplementary Figure 1). We next investigated the
response of LCLs to both drugs. All 3 CMMRD-derived LCLs
were phenotypically distinguishable from cells with hetero-
zygous or wild-type MMR status. They displayed better cell
survival compared to controls and there was no overlap be-
tween the two groups under several MNNG experimental














We next sought to identify experimental conditions that
would best discriminate CMMRD patients from controls.
Among 42 patients collected from several European cancer
centers (including the 3 patients previously analyzed in the
proof of concept study), 19 had been diagnosed as definite
CMMRD cases by molecular analysis, ie, bi-allelic pathogenic
MMR gene alterations. Of these, LCLs from 14 cases were
available for the present case-control study (Table 1 and
Figure 2). Pedigrees for all previously unreported patients
are shown in Supplementary Figure 2. Clinical and tumor
data together with detailed results of germline MMR anal-
ysis are provided in Supplementary Table 1.
evMSI. LCLs from the 14 CMMRD patients comprising
carriers of bi-allelic mutations in PMS2 (n ¼ 10), MSH6 (n ¼
3) or MLH1 (n ¼ 1) displayed microsatellite deletions
ranging from 1 to 7 base pairs. Detection of the evMSI
phenotype in the cell lines was achieved 120 days after
immortalization at the latest. The median culture time for a
positive evMSI phenotype was 83.6 ± 22.6 days (range 45-
120) (Supplementary Table 2). In contrast, LCLs from all 23
MMR-proficient controls (12 LS patients and 11 MMR=
Figure 1. Proof of concept study. (A) LCLs but not PBLs from co
Electrophoretograms of fluorescent amplification products for
predominant allele in base pairs (bp) and the fluorescence inten
arrows) occurred at these loci in lymphoblastoid cell lines (LCLs
(MSH6 deficient), and C15 (MLH1 deficient) compared with their
PCR profiles were similar in CMMRD patients C01.1 and C14 an
be demonstrated ex vivo. (B) CMMRD patients but not controls
each marker and the cumulative size of deletion (ie, the sum of th
from the 3 CMMRD patients but not those from MMR-proficien
wild-type (wt) MMR status. (C) LCLs from CMMRD patients di
MNNG treatment at 24-hour intervals were performed. LCLs fr
guishable from heterozygous (green) and wild-type (blue) LCLs,
LCLs from the 3 CMMRD patients (red), 4 LS patients (green),wild-type individuals) showed no deletions. For all 23
controls except two, the cell lines were grown for at least
120 days without any evidence of deletions (median culture
time ¼ 175 days ± 62.6, range 83-304 days). Five control
cell lines were grown for longer than 220 days without any
evidence of deletions. Therefore, for subsequent experi-
ments the cut-off value used to define a cell line as positive
for evMSI was set as a 1 base pair deletion across all three
markers and a maximum culture time of 120 days was used.
Drug tolerance assays. By varying the MNNG con-
centration and number of treatments, we found the optimal
experimental condition that allowed CMMRD patients to be
discriminated from controls was two rounds of 2.5 mM
MNNG. Using this condition, LCLs from all 14 CMMRD pa-
tients displayed a cell survival rate above 60%. In contrast,
51/52 LCLs from controls displayed a cell survival rate
lower than 40% (median cell survival rates of 87.5% and
20.9%, respectively; P < .0001; Student t test) (Figures 3
and 4A). At an arbitrary cut-off value of 50% cell survival,
the methylation tolerance assay was therefore shown to be
100% sensitive (14 of 14) and 98% specific (51 of 52; the
positive sample was from an LS patient with an MSH6
defect). The thiopurine tolerance test was found to be less
discriminatory and hence was not continued further
(Supplementary Figure 3). This result concurs with previous
findings that MMR-deficient cells are 100-fold more tolerant
than MMR-proficient cells to death induced by methylating
agents, but only about 10-fold more tolerant to 6-TG
treatment.23
Overall, evMSI and methylation tolerance assays were
found to be highly specific and sensitive and gave concor-
dant results for all cases tested with both methods. In
subsequent studies we therefore deemed that both assays
must show abnormal results in order to conclude a definite
diagnosis of CMMRD. To rule out a diagnosis of CMMRD,
both assays should display normal results. Diagnosis should
be considered as doubtful if results from the two functional
tests are discordant.
Application of Functional Tests for Detection of
CMMRD in At-Risk Individuals
In 23 of the 42 patients from our series, a diagnosis of
CMMRD was suspected based on clinical presentation, but
the diagnosis could not be confirmed by MMR gene muta-
tion analysis (Table 1, Figure 2). These comprised 8 patientsnstitutional MMR deficiency (CMMRD) patients display evMSI.
NR27, NR21, and BAT26 microsatellites. The length of the
sity are indicated in the box below each profile. Deletions (red
) derived from CMMRD patients C01.1 (PMS2 deficient), C14
respective peripheral blood lymphocytes (PBLs). In PBLs, the
d their respective parents, demonstrating that MSI could only
display evMSI. Deletions, expressed as the size of deletion for
e deletions observed in the 3 markers) were observed in LCLs
t controls, which included 4 LS patients and 1 individual with
splayed methylation tolerance. One, two, or three rounds of
om the 3 CMMRD patients (red) were phenotypically distin-
using several experimental conditions. (D) 6-TG response of
and 1 individual with wild-type MMR status (blue).





Study, reference (country)Gene Mutation type Class Status
CMMRD patients with confirmed molecular diagnosis (ie, with bi-allelic pathogenic MMR gene alterations)
C01.1 7 PMS2 Frameshift / Missense DM / DM Compound heterozygous Auclair et al, 200732
C01.2 7 PMS2 Frameshift / Missense DM / DM Compound heterozygous Auclair et al, 200732
C02 3 PMS2 Frameshift / Frameshift DM / DM Homozygous Ilencikova (Slovakia)
C03.1 8 PMS2 Frameshift / Frameshift DM / DM Homozygous Patient 1 in Chmara
et al, 201333
C03.2 9 PMS2 Frameshift / Frameshift DM / DM Homozygous Patient 1.2 in Chmara
et al, 201333
C04 7 PMS2 Large deletion / Large deletion DM / DM Compound heterozygous Patient 2 in Chmara
et al, 201333
C05 10 PMS2 Nonsense / Nonsense /
Frameshift
DM / DM / DM Compound heterozygous Brugières (France)
C06 8 PMS2 Splice / Splice DM / DM Homozygous Brugières (France)
C07 8 PMS2 Missense / Missense DM / DM Homozygous Colas (France)
C08 8 PMS2 Missense / Missense DM / DM Homozygous Malka (France)
C09.1 5 PMS2 Splice / Splice DM / DM Homozygous Brugières (France)
C10 4 PMS2 Splice / Splice DM / DM Homozygous Brugières (France)
C11 11 PMS2 Large deletion / Large deletion DM / DM Homozygous Fedhila (Tunisia) / Colas (France)
MSH2 Missense VUS Heterozygous
MSH6 Missense VUS Heterozygous
C12 5 MSH6 Frameshift / Frameshift DM / DM Homozygous Patient PIV.5 in Ilencikova
et al, 201134
C13.1 10 MSH6 Frameshift / Frameshift DM / DM Compound heterozygous Patient P6 in Gardes
et al, 201235
C14 8 MSH6 Frameshift / Frameshift DM / DM Compound heterozygous Auclair et al, 200732
C15 10 MLH1 Splice / Splice DM / DM Homozygous Entz-Werle (France)
C16 9 MLH1 Missense / Missense DM / DM Homozygous Raevaara et al, 200436
C17 6 MSH2 Large deletion / Large deletion DM / DM Homozygous Verloes (France)
Patients with clinical characteristics of CMMRD syndrome but a lack of confirmatory standard genetic defect
C18 6 PMS2 In frame deletion / Missense DM / VUS Compound heterozygous Lejeune (France)
C19 8 PMS2 Missense / Frameshift VUS / DM Compound heterozygous Mathieu-Dramard (France)
C20.1 7 MSH6 Missense / Missense VUS / VUS Homozygous Leis (Afghanistan)
C20.2 7 MSH6 Missense / Missense VUS / VUS Homozygous Leis (Afghanistan)
C21 14 MSH6 Frameshift / In frame deletion DM / VUS Compound heterozygous Bougeard et al, 201429
MSH2 Missense VUS Heterozygous
C22 8 MSH6 Missense / Missense VUS / VUS Homozygous Wafaa (Marocco)/ Colas (France)
PMS2 Missense VUS Heterozygous
C23 13 MSH6 In frame duplication / In frame
duplication
VUS / VUS Heterozygous Gauthier-Villars (France)
C24 6 MSH2 Splice / Splice DM / VUS Compound heterozygous Ruiz-Ponte (Spain)
C25 5 PMS2 Frameshift DM Heterozygous Colas (France)
C26 4 PMS2 Large deletion DM Heterozygous Kinzel (Germany)
C27 3 MLH1 Frameshift DM Heterozygous Colas (France)
MSH2 Missense VUS Heterozygous
C28 1 MLH1 Splice DM Heterozygous Caron (France)
C29.1 4 - No MMR mutation identifiedb - - Brugières (France)
C30 4 MSH2 Splice VUS Heterozygous Brugières (France)
C31 3 - No MMR mutation identified - - Mortemousque (France)
C32 3 - No MMR mutation identified - - Brugières (France)
C33 4 - No MMR mutation identified - - Wang (France)
C34.1 4 - No MMR mutation identified - - Grandjouan (France)
C35 6 - No MMR mutation identified - - Brugières (France)




ATwith bi-allelic MMR mutations that included one or two VUS,
5 patients with a single MMR mutation and 10 patients in
which no MMR mutation was detected. We evaluated these
patients using the functional assay conditions describedabove (Table 2, Figure 4B). Six patients displayed positive
results for both the evMSI and methylation tolerance assays,
indicating a highly probable diagnosis of CMMRD. They






Study, reference (country)Gene Mutation type Class Status
C36 3 - No MMR mutation identified - - Grandjouan (France)
C37 4 - No MMR mutation identified - - Colas (France)
C29.2 NA - No MMR mutation identifiedb - - Brugières (France)
C34.2 4 - No MMR mutation identified - - Brugières (France)
NOTE. Detailed description of the MMR gene alterations is provided in Supplementary Table 1.
DM, deleterious mutation; NA, not applicable; VUS, variant of unknown significance.
aClinical score according to Wimmer et al.9
bExtensive genetic screening was performed post-hoc in view of the abnormal functional assay results found in patient C29.1.
It led to the identification of a homozygous deletion of exons 14-15 of the PMS2 gene, c.276-? (*160?) del, whereas the brother
(patient C29.2) was found to be heterozygous for the PMS2 deletion.
October 2015 Functional Diagnosis of CMMRD Syndrome 1023alterations comprising VUS. Consistent with our results, in
silico prediction favored a pathogenic nature for the MSH6
and PMS2 variants in four of these patients (C20.1, C20.2,
C18, C22). In the sixth patient (C29.1), no apparent germline
MMR mutations were detected. In another 15 patients,
evMSI and methylation tolerance assays were both negative,
indicating that a diagnosis of CMMRD was very unlikely.
These included one compound heterozygote for an MSH2
variant, 5 patients with a single MLH1, PMS2, or MSH2
alteration, and 9 patients where no MMR alteration had
been detected. In the two remaining patients (C21 and C23,Figure 2. Flow diagram of
patient study cohort. The
functional assay, which in-
cludes the evMSI and
methylation tolerance tests,






VUS, variant of unknown
significance.with bi-allelic MSH6 mutations comprising one or two VUS,
respectively), the data showed methylation tolerance but no
evMSI phenotype. We therefore concluded a result of
“doubtful” for both patients.Comparison of Functional Assays With Other
Methodological Approaches
We trialed a recently described method that evaluates
dinucleotide repeats for the detection of MSI in germline













Figure 3. Tolerance of immortalized lymphoblasts derived from 14 constitutional MMR deficiency (CMMRD) patients and a
series of MMR-proficient controls (including LS patients and MMR wild-type individuals) to increasing concentrations of
MNNG. Because of the short half-life of MNNG in aqueous solution, 1, 2, or 3 pulses of treatment were performed. With the
exception ofMLH1þ/ lymphoblastoid cell line (LCLs; n ¼ 11) that behaved similarly to MMR wild-type lymphoblasts (n¼ 12) in
all experimental conditions, MSH2þ/ (n ¼ 12), PMS2þ/ (n ¼ 4), and mainly MSH6þ/ cell lines (n ¼ 13) exhibited increased
cell survival under low MNNG concentrations. At higher MNNG concentrations and/or increasing numbers of drug treatments,
the survival ofMSH2þ/, PMS2þ/, andMSH6þ/ lines decreased towards that ofMLH1þ/ and MMR wild-type cells, whereas
CMMRD LCLs remained quite tolerant to the drug. The best experimental condition to discriminate CMMRD patients from
controls was 2 rounds of 2.5mM MNNG (red box). Patients with CMMRD or LS are represented with distinct colors depending
on the MMR gene that was mutated (red for PMS2, blue for MSH6, yellow for MSH2, and green for MLH1).




ATyielded interpretable results in 15 of 18 CMMRD patients
and in 16 of 19 controls. CMMRD patients with bi-allelic
mutations involving PMS2 (n ¼ 11), MLH1 (n ¼ 1), or
MSH2 (n ¼ 1) displayed abnormal gMSI values. In agree-
ment with the original report,24 we found however that
CMMRD patients with bi-allelic deleterious mutations
involving MSH6 (n ¼ 2) displayed normal gMSI ratios, thus
reducing the sensitivity of this method (Table 2 and
Supplementary Table 3 and Supplementary Figure 4). gMSI
ratios were normal for all controls. gMSI also yielded
interpretable results in 21 of 23 patients suspected of
having CMMRD. The five carriers of bi-allelic MSH6 alter-
ations displayed normal gMSI, as expected. Moreover, gMSI
corroborated the results of our functional assays in all pa-
tients with PMS2, MLH1, or MSH2 mutations, with the
exception of one (C18). This patient carried one deleterious
mutation and one VUS in the PMS2 gene. He displayed
normal gMSI but abnormal evMSI and methylation tolerance
results (Table 2). The c.2249G>A missense mutation found
in the PMS2 gene of patient C18, together with complete
deletion of the other PMS2 allele, was previously reported in
a patient diagnosed with rectal cancer and a brain tumor at22 and 23 years of age, respectively.25 This further cor-
roborates a pathogenic role for the VUS in patient C18 and is
consistent with the results of our functional assay. The
evMSI, methylation tolerance and gMSI assay results were
all abnormal in patient C29.1 who lacked apparent MMR
germline mutations. This prompted us to conduct additional
PMS2 screening using multiplex ligation-dependent probe
amplification, which led to the identification of a homozy-
gous deletion of exons 14-15. Normal functional test results
and gMSI ratio were found in an asymptomatic brother aged
11 years (C29.2) who was later found to be heterozygous
for the PMS2 deletion.
Another tool proposed for CMMRD screening is IHC
analysis to detect loss of MMR protein expression in
normal tissues. IHC was recently reported to be 100%
sensitive when performed on normal colonic or skin tis-
sues from 5 CMMRD patients.26 However, based on previ-
ous observations in LS patients, IHC may lack sensitivity,
especially for the detection of some missense and trun-
cating MMR gene mutations,27,28 resulting in false negative
diagnosis for CMMRD. This was demonstrated in the pre-
sent study where positive MSH6 staining was observed in
Figure 4. evMSI andmethylation tolerance assays in a case-control study (A) and in patients considered at-risk for constitutional
MMR deficiency (CMMRD) syndrome (B). (A) Case-control study involving 14 CMMRD patients and 23 MMR-proficient controls
consisting of 12 LS patients with heterozygous mutations affecting the MMR genes and 11 patients with no detected germline
MMRmutation. EvMSI assay (left): deletion sizes (in base pairs [bp]) are expressed as the sum of the deletions for the 3 markers
(NR27,NR21, andBAT26). The cut-off value used to define acell line as positive for evMSIwas set at 1 bpdeletion for all 3markers
(red dotted line). Lymphoblastoid cell line (LCLs) from all 14 CMMRD patients showed decreased allele size, regardless of which
MMR gene was mutated, whereas no deletions were detected in the 23 MMR-proficient controls tested. Methylation tolerance
assay (right): survival (%) of immortalized lymphoid cells derived from the same 14 CMMRD patients and from controls after 2
rounds of 2.5 mMMNNG treatment. Because some LS patients displayed increased tolerance toMNNGcompared toMMRwild-
type controls, a larger series of LS patientswas used for the drug assay.WhereasMLH1þ/ LCLs behaved similarly toMMRwild-
type lymphoblasts,MSH2þ/ and especiallyMSH6þ/ cell lines exhibited significantly increased median cell survival. Overall, all
CMMRD-derived LCLs displayed cell survival higher than 60%, whereas cell survival of all MMR-proficient LCLs was lower than
40%, with the exception of 1 case. The cut-off value was arbitrarily set at 50% cell survival (red dotted line). Student t test.
(B) evMSI (left) and methylation tolerance (right) tests were applied for the detection of CMMRD syndrome in 23 patients with a
clinical presentation suggestive of CMMRD but for whom the diagnosis could not be confirmed (or excluded) by sequencing of
MMR genes. These consisted of 8 patients with biallelic MMR alterations involving 1 or 2 VUS, 5 patients with a single MMR
alteration, and 10 patients without germlineMMRmutation. One of these last patients (C29.1) showed abnormal functional assay
results for both tests, which prompted us to perform additional PMS2 genetic screening that led to the identification of a ho-
mozygous deletion. Vertical line ¼ VUS; cross ¼ deleterious mutation. CMMRD and LS patients are represented using distinct
colors depending on the MMR gene that was mutated.













ATtwo patients (C20.2 and C22) with homozygous MSH6
missense mutations and who are likely to be CMMRD ac-
cording to the functional assays and in silico predictions.
Conversely, PMS2 protein was not expressed in the normal
colonic mucosa of patient C25, the carrier of a single
deleterious PMS2 mutation in which a diagnosis of CMMRD
was ruled out based on normal results for the evMSI,
methylation tolerance, and gMSI tests (Table 2 and
Supplementary Table 1).Estimation of Sensitivity, Specificity, Positive
Predictive Value, and Negative Predictive Value
for Functional Assays and for Other
Methodological Approaches
In our case-control cohort, the functional assay (ie,
evMSI and methylation tolerance) was 100% sensitive and
100% specific whereas gMSI testing was 86.7% (13/15)
sensitive and 100% (16/16) specific. It is worth noting that
the sensitivity of gMSI is likely to be an overestimate, since
Table 2.evMSI, Methylation Tolerance, gMSI, and IHC Data in the Series of 14 CMMRD Patients With Bi-Allelic Pathogenic
MMR Gene Alterations and in 23 At-Risk Patients for Whom Diagnosis Could Not Be Confirmed by MMR Sequencing
Patient




Comparison with other tests




in normal tissue (IHC)
CMMRD patients n¼14
C15 hmz DM MLH1 CMMRD Lost
C06, C07, C08, C09.1 hmz DM PMS2 Lost
C10 hmz DM PMS2 þ þ þ NA
C04, C05 cpd htz DM PMS2 Lost
C01.1 cpd htz DM PMS2 NA
C01.2 cpd htz DM PMS2 þ þ NA Lost
C02 hmz DM PMS2 þ þ NI NA
C14 cpd htz DM MSH6 Lost
C12 hmz DM MSH6 þ þ - NA
C13.1 cpd htz DM MSH6 NA
Patients at-risk for CMMRD n¼23
C29.1 No mutationa þ þ CMMRD þ Lost
C20.1 hmz VUS MSH6 þ þ - Lost
C20.2, C22 hmz VUS MSH6 Conserved
C18 DM þ VUS PMS2 Lost
C19 DM þ VUS PMS2 þ þ NI Lost
C24 DM þ VUS MSH2 - - Not CMMRD - Conserved
C30 htz VUS MSH2 NA
C25 htz DM PMS2 Lost
C26 htz DM PMS2 Conserved
C27 htz DM MLH1 NA
C28 htz DM MLH1 Conserved
C34.2 No mutation Conserved
C29.2, C31, C32, C34.1,
C35, C36, C37
No mutationa NA
C33 No mutation - - NI NA
C21 DM þ VUS MSH6 - D Doubtful - Lost
C23 hmz VUS MSH6 Lost
NOTE. Detailed data on MMR gene alterations, on the expression of MMR proteins in normal tissue, and on gMSI test are
provided in Supplementary tables 1 to 3.
, negative/normal; þ, positive/abnormal; cpd, compound; DM, deleterious mutation; hmz, homozygous; htz, heterozygous;
NA, not available; NI, not interpretable; VUS, variant of unknown significance
aExtensive genetic screening that was performed post-hoc led to the identification of a deletion of exons 14-15 in the PMS2
gene that was found at an homozygous or heterozygous status in patients C29.1 and C29.2, respectively.




ATthis depends on the proportion of CMMRD patients with
MSH6 alterations. In our series this was only 13% (2/15),
however MSH6 alterations are thought to be responsible for
a higher proportion (w20%) of all CMMRD patients.9 The
performance of IHC could not be evaluated properly due to
the lack of a standardized method for the analysis of MMR
gene expression in the normal tissue of controls (ie,
MMR-proficient cases).
Next, we estimated the performance of functional testing
compared to the standard method of MMR gene sequencing.
This was done for the entire cohort, including patients
deemed to be at-risk. Using a Metropolis-Hastings algorithm,
the functional assay revealed higher sensitivity (94.2%
(95% CI: 79.4%-99.9%) vs 80.1% (54.1%-99.0%)), higher
NPV (97.2% (89.8%-99.9%) vs 91.2% (76.6%-99.6%)), but
lower specificity (90.1% [range, 76.1%-99.5%] vs 97.6%
[range, 91.2%-99.9%]) and lower PPV (80.5% [range,
53.9%-99%] vs 93.6% [range, 77.9%-99.8%]) for CMMRDdiagnoses. In order to include gMSI in the comparison, an
estimation of the sensitivity and specificity was made in the
smaller series of patients and controls for which results
from all tests were available. Functional testing still offered
the highest sensitivity (93.3% [range, 76.7%-99.8%]) and a
lower specificity (Supplementary Table 4), however
these differences did not reach statistical significance
because of small cohort sizes. As stated above, the lack of a
standardized method for IHC analysis of normal tissues
meant we were unable to properly evaluate the sensitivity
and specificity of this method.Discussion
In this article, we propose a new approach for the
diagnosis of CMMRD that involves the common and spe-
cific functional characteristic of all CMMRD patients
(ie, MMR deficiency). Our approach was based on the
Figure 5. Proposed algorithm for the evaluation of patients
suspected of having constitutional MMR deficiency
(CMMRD). In the future, individuals with a clinical score of
3 according to Wimmer et al9 should be initially tested by
functional assays. Because this approach has a high
negative predictive value, a normal result obtained with the
functional assays would confidently allow diagnosis of
CMMRD to be excluded without the need for additional
tests. Alternatively, an abnormal result would be highly
suggestive of CMMRD. However, due to the relatively low
positive predictive value (80.5%) associated with this assay,
we recommend that medical geneticists and pediatricians
further investigate these “at-very-high-risk” cases by using
other approaches (immunohistochemistry [IHC], germline
microsatellite instability [gMSI], or sequencing of MMR
genes) in order to confirm the diagnosis. It is worth noting
that IHC results can be used to guide germline mutation
analysis to a specific MMR gene, whereas in this context,
the finding of a normal gMSI ratio would direct genetic
analysis to the MSH6 gene. *LS should be sought in cases
with evocative criteria.













ATexploitation of this feature through the evaluation of MSI
and methylation tolerance in MMR-deficient, immortalized
lymphoblastoid cells. This method gave unequivocal re-
sults in CMMRD patients with known bi-allelic deleterious
mutations. If one assumes that abnormal results for both
assays indicate a diagnosis of CMMRD, whereas normal
results for both assays rule this out, our method was
100% sensitive and 100% specific in this case-control
study. When applied to additional patients suspected of
having CMMRD syndrome because of evocative clinical
criteria but who lacked the confirmatory standard genetic
defects, a clear discrimination into two groups was ob-
tained. In the first group showing abnormal results for
both tests, we considered that CMMRD was highly prob-
able. In contrast, a diagnosis of CMMRD was highly un-
likely in the second group of patients showing normal
results for both tests. Our novel functional approach may
therefore be especially useful for the confirmation or
rejection of CMMRD diagnosis in patients with VUS by
providing an assessment of the pathogenicity of MMR
variants. It is also useful in cases where the diagnostic
method failed to detect bi-allelic MMR mutations despite
an evocative CMMRD clinical phenotype (eg, patient
C29.1). Furthermore, our approach can rule out that a
second mutation has been missed in patients with het-
erozygous, pathogenic PMS2 or MSH2 mutations who
nevertheless show an unusually early onset of cancer
(eg, colon tumors at 12, 17, and 25 years of age in patients
C24, C26, and C25, respectively). The results from our
functional approach support the existence of a clinical
continuum that spans the less severe CMMRD phenotypes
that mimic LS (eg, patient C18), to more severe and early
onset LS phenotypes that mimic CMMRD.29 Overall, our
findings highlight that functional tests capable of assessing
constitutional MMR-deficiency are highly desirable for the
accurate diagnosis of CMMRD patients.
Although we have investigated by far the largest CMMRD
series reported to date in the literature, our method re-
quires further confirmation in additional cohorts of CMMRD
patients. This will help to refine the criteria for the func-
tional assays in cases with ambiguous results, such as the
two patients who harbored VUS in the MSH6 gene and
showed methylation tolerance but not evMSI (C21, C23).
One possible explanation for this observation is that certain
MMR gene mutations might uncouple the DNA mismatch
repair and DNA damage-induced apoptosis functions, as
reported in mice.30,31 Overall, we found that functional
testing showed better sensitivity than either MMR gene
sequencing or gMSI, although it may have a lower speci-
ficity. Bearing this in mind, we propose a flow chart for the
use of our assay alone or in combination with other tests in
routine clinics in the next future (Figure 5). IHC could not be
evaluated properly in this study due to the lack of a stan-
dardized method for assessment of MMR gene expression in
the normal tissues of MMR-proficient subjects. The results
with IHC are likely to be highly dependent on the type of
tissue being studied (eg, colon, brain, skin, lymphoid cells).
Moreover, it is well known that IHC can give rise to false
negative results for MMR deficiency in cases whereinactivating missense mutations nevertheless result in
expression of the mutant protein.27,28 Further studies
should evaluate MMR protein expression using standardized
methods in normal and tumor tissues from large cohorts of
CMMRD patients, MMR-proficient controls and Lynch syn-
drome patients, in the same manner as performed here to
assess our functional assay.
In summary, the novel functional approach proposed
here showed higher sensitivity for CMMRD diagnosis
compared to MMR sequencing or gMSI, the 2 other methods
used so far. This approach can be used to determine
whether MMR variants of uncertain pathogenicity are
responsible for functional inactivation of the MMR system.
The ability to classify variants as pathogenic or neutral is a
major challenge in clinical genetics, particularly with the
advent of next-generation sequencing. Moreover, the diag-
nosis of CMMRD syndrome based solely on clinical and
genetic data is presently inadequate. As an overall diag-
nostic strategy, we therefore recommend the implementa-
tion of our functional assays in combination with IHC and
gMSI analysis (Figure 5). These tests can be performed in
any order upon suggestion of CMMRD syndrome based on
an evocative clinical score. This strategy has already been
introduced at the Saint-Antoine Hospital in Paris with the
aim of further validating our assay in an independent cohort
of CMMRD patients. The service is available upon request.
We are confident this assay will provide a functional




ATdefinition, or “signature,” for CMMRD, similar to the chro-
mosomal breakage test for diagnosis of Fanconi anemia. In
the near future, we believe that individuals who are at-risk
of CMMRD will be tested solely using functional assays as
the initial test.Supplementary Material
Note: To access the supplementary material accompanying
this article, visit the online version of Gastroenterology at
www.gastrojournal.org, and at http://dx.doi.org/10.1053/
j.gastro.2015.06.013.References
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Supplementary Material and Methods
Patients
All 19 genetically confirmed and 19 of 23 patients
suspected of having constitutional mismatch repair
(CMMRD) included in this study had a score 3 points
according to the recently published clinical criteria for
suspected diagnosis of CMMRD. Additionally, 4 patients
were included in this study. One patient (C28) was included
because he displayed a very severe clinical history with 4
Lynch syndrome (LS)-related tumors from 32 to 36 years of
age and osteosarcoma at 11 years of age (osteosarcoma
was found in CMMRD patient C05 at 24 years of age).
Equally, 1 patient (C27) was included because, compared to
other members of this LS family, he had a very early onset
(30 years of age) of 2 synchronous colon cancers with an
adenoma and a brother who had a malignant brain tumor
at the age of 18 years old. Another patient (C33) had a
cerebral tumor at 27 years of age as well as café-au-lait
macules (CALMs), and her sister displayed a cerebral tumor
(22 years of age). Finally, 1 patient was an asymptomatic
sibling with CALMs of a possible CMMRD patient (C29.2).
Altogether, the study included 42 patients (37 families)
from several European cancer centers. Control subjects
considered free of MMR germline defects included 5 fa-
milial adenomatous polyposis (FAP) and 2 neurofibroma-
tosis type 1 (NF1) individuals with identified germline APC
and NF1 mutations, respectively (FAP and NF1 were chosen
because they represented cancer predisposition syndromes
showing clinical overlap with CMMRD), and 8 control pa-
tients had diagnoses of sporadic colorectal cancer without
familial cancer history. These patients had developed mi-
crosatellite stable tumors (6 cases) or microsatellite insta-
bility (MSI) tumors due to epigenetic silencing of MLH1
because of somatic methylation (2 cases) and thus were not
suspected of having CMMRD syndrome.
Colorectal Cell Lines
Human colorectal cancer cell lines were grown in Dul-
becco’s modified Eagle medium (DMEM) with stable gluta-
mine (Glutamax) supplemented with 10% fetal calf serum,
100 IU/mL penicillin and 100 mg/mL streptomycin (PAA).
They included 6 microsatellite unstable (HCT116, LIM2405,
LS174T, KM12 [all MLH1-deficient], HCT15 [MSH6
mutated], and LoVo [homozygous deletion of exons 2-8 of
MSH2]) and 5 microsatellite stable (LS513, SW620, Caco-2,
FET, and HCT116 mlh1-2 [HCT116 transfected with an
MLH1-expression vector]1) cell lines.
Treatment of Colorectal Cell Lines
Cells in the exponential growth phase were counted by
Trypan blue exclusion and seeded into 24-well plates
(Falcon) at a density of 0.2 to 5  105 cells/well in com-
plete medium. After 24-hour incubation, 6-TG (1, 5, 15, and
20 mM final concentrations) or extemporaneously recon-
stituted MNNG (0.1, 1, 5, 20 mM final concentrations) was
added. Medium was removed and replaced with fresh
medium after 24-hour or 1-hour incubation, respectively.
Cell growth was evaluated after a total incubation period of
7 to 9 days. To exclude differences in MNNG cytotoxicity
due to variations in O6-methylguanine methyltransferase
enzyme activity, the latter was abrogated by exposure to
O6-benzylguanine (20 mmol/L final concentration) during
the entire experiment. All samples were tested in
quadruplicate.
6-TG Treatment of Lymphoblastoid Cell Lines
Cells suspended in complete medium (3x105 cell/mL)
were distributed into 6 microtubes with increasing con-
centrations of 6-TG (0.15, 0.3, 0.6, 1.25, and 2.5 mmol/L final
concentrations) into 5 of them. After 24-hour incubation, all
microtubes were centrifuged, and cells were rinsed with
fresh medium and then seeded in 100-mL aliquots into
96-well round-bottom plates (0.6104 cells/well). Cell
growth was evaluated after a total incubation time of 7
days, and all samples were tested in sextuplicate.
DNA Extraction for evMSI and gMSI Assays
Ficoll-Plaque PLUS (GE Healthcare) was used to isolate
human lymphocytes from blood patients, according to the
supplier’s recommendations. DNA extraction from lym-
phocytes or lymphoblastoid cell line (LCL) was performed
using QIAmp DNA kit according to the supplier’s recom-
mendations (Qiagen, Venlo, The Netherlands).
Determining the gMSI Ratio
Multiplex PCR amplification in triplicate (denaturation
of 95C for 2 min, followed by 35 cycles of 95C for 30
seconds, 55C for 30 seconds, and 72C for 60 seconds, with
a final extension at 72C for 10 minutes) of the dinucleotide
microsatellite markers D17S791, D2S123, and D17S250
was developed using the primers previously described,2
and using 10 ng of patient germinal DNA. PCR products
were separated by capillary electrophoresis on an ABI3100
genetic analyzer and quantified using Gene Mapper version
3.7 software. Briefly, the germline microsatellite instability
(gMSI) ratio was determined by dividing the height of an
allele’s trailing “stutter” peak (nþ1) by the height of the
allele’s major peak (n). Interpretation required that the size
difference between alleles in heterozygous individuals was
6 bp.2
Statistical Analysis
We developed a Bayesian approach to conduct infer-
ence for the unknown prevalence, sensitivity, and speci-
ficity of the 3 diagnostic methods as performed in Joseph
et al.3 Our setting, however, was different from theirs, in
particular, we knew the true disease status for controls
and genetically confirmed CMMRD patients, which
removed the lack of identifiability of in the approach
used by Joseph et al, which was pointed out in Johnson
et al.4
In the saturated model, the joint distribution of the
tests or combination of tests was assumed to be multino-
mial with 16 categories, corresponding to all possible
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observations. The multinomial parameters were expressed
as the true proportion of confirmed CMMRD patients,
sensitivity, and specificity of the tests. We assumed condi-
tional independence of the tests to ensure identifiability in
the unsaturated model. A Metropolis-Hastings algorithm
was run on the data to estimate the 7 parameters and
2-sided confidence intervals.3,5 Let D be the true CMMRD
status (þ/), T1 (þ/), T2 (þ/) and T3 (þ/) be the
result of MMR gene sequencing, functional testing and gMSI
testing, respectively. The true proportion of CMMRD pa-
tients, sensitivity, and specificity of the 3 tests or combi-
nation of tests are defined as:
p ¼ ℙðD ¼ þÞ
s1 ¼ ℙðT1 ¼ þjD ¼ þÞ and c1 ¼ ℙðT1 ¼ jD ¼ Þ
s2 ¼ ℙðT2 ¼ þjD ¼ þÞ and c2 ¼ ℙðT2 ¼ jD ¼ Þ
s3 ¼ ℙðT3 ¼ þjD ¼ þÞ and c3 ¼ ℙðT3 ¼ jD ¼ Þ
The observed data are summarized in Supplementary Table
5 (rows with no observations are not reported); the usual
latent variables are denoted by X, Y, and Z.
We particularized MSH6 cases, as gMSI is not relevant to
identify CMMRD patients with MSH6 defects. As a conse-
quence, we rewrite
conditionally to the parameters.
This formulation allowed us to fit the model through the
Metropolis-Hastings algorithm.6 In this algorithm, we
considered a Dirichlet prior for the joint distribution of
the seven parameters. Parameters of the marginal previ-
ous distributions were chosen as (1,1) for the true pro-
portion of CMMRD patients, the sensitivities and the
specificities. The Metropolis-Hastings algorithm was run
on 50,000 iterations, and the last 25,000 iterations were
used to derive estimations and confidence intervals for
the sensitivities, specificities, positive and negative pre-
dictive values of MMR gene sequencing, functional testing
and gMSI testing. The same procedure has been applied
for the comparison between MMR gene sequencing and
functional testing.
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and evMSI gMSI True status Data
þ þ þ CMMRDþ 9
þ þ - CMMRDþ 2
- - - CMMRDþ Y
- - - CMMRD- 9þ15-Y
- þ þ CMMRDþ X
- þ þ CMMRD- 1-X
- þ - CMMRDþ Z
- þ - CMMRD- 4-Z
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